Results 161 to 170 of about 37,789 (262)

Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management

MedComm, Volume 7, Issue 9, September 2026.
The clinical manifestations of PFO. Although the majority of PFOs are benign and asymptomatic, they can present with a variety of clinical manifestations, or coexisting with other diseases and aggravating their symptoms, including cerebral diseases (such as CS, epilepsy, TIA, or migraine), systemic embolism (such as embolism in renal artery, coronary ...
Linlin Meng, Xiaotong Zhang, Guangrui Sun, Honggang Dai, Xiao Meng, Cheng Zhang, Yun Zhang   +6 more
wiley   +1 more source

LDLR [PDF]

, 2019
openaire   +1 more source

Tissue‐Resident Macrophage in Inflammation and Cancer

MedComm, Volume 7, Issue 9, September 2026.
Opposing macrophage functions in inflammation and cancer converge on shared mechanistic nodes, informing cross‐disease therapeutic strategies. ABSTRACT Tissue‐resident macrophages (TRMs) are long‐lived immune cells strategically distributed across organs, where their functional plasticity enables both homeostatic maintenance and pathological ...
Siyuan Huang, Jiangbo Fan, Wenyi Liu, Di Liu, Rui Wang, Yuanyang Wang, Jianhui Sun, Huacai Zhang, Qingli Cai, Zhe Xu, Fang Xu, Jianxin Jiang, Zhen Wang, Ling Zeng   +13 more
wiley   +1 more source

LDLR Chaperone MESD [PDF]

, 2020
openaire   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source

LDLR Variant Classification Through Activity-Normalized Prime Editing Screening. [PDF]

Circulation
Zhou PJ, Velimirovic M, Yu T, Gligorovski V, Mathis N, Zhao J, Phan QV, Vogd F, Ryu J, Pan Q, Tyagi A, Ascher DB, Schwank G, Pinello L, Cassa CA, Sherwood RI.   +15 more
europepmc   +1 more source

Optical mapping reveals a higher level of large‐scale structural variants in a family with paternally transmitted myotonic dystrophy and independent Parkinson's disease

The Journal of Pathology, Volume 270, Issue 1, Page 83-97, September 2026.
Abstract Myotonic dystrophy type 1 (DM1) is a clinically challenging multisystem neuromuscular hereditary disorder, with generational increase in severity and earlier age at onset. It is caused by an unstable cytosine‐thymine‐guanine repeat expansion at the DMPK locus, accompanied by associated genetic and epigenetic modifications.
Md Mehedi Hasan, Jenna Craddock, Tingting Gong, Ruth J Lyons, Igor Stevanovski, Sanjog R Chintalaphani, Ira W Deveson, Weerachai Jaratlerdsiri, Kishore R Kumar, Vanessa M Hayes   +9 more
wiley   +1 more source

Is FH a curable disease? [PDF]

Glob Cardiol Sci Pract
Seidah NG.
europepmc   +1 more source

Deciphering the Mechanisms of Statin–Ezetimibe Drug Combinations Using Boolean Logical Modeling and Transcriptomic Data

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT Drug Combinations offer increased therapeutic efficacy and reduced toxicity compared with single agents. Understanding a drug combination's mechanisms of action (MoA) can provide important insights into therapeutic efficacy. The MoA of many FDA‐approved drugs, however, often remains unclear.
Rui‐Sheng Wang, Matteo Pedrelli, Osman Ahmed, Garagnani Paolo, Paolo Parini, Joseph Loscalzo   +5 more
wiley   +1 more source

Putative protective role of <i>PCSK9</i> variants in a multigenerational family with familial hypercholesterolemia. [PDF]

Atheroscler Plus
Rodríguez-Nóvoa S, Martínez Hernández P, Hidalgo Mayoral I, Herranz Cecilia A, Rodríguez Roca N, Carazo Álvarez A, Gallego Onís N, Duque Alcorta M, Rodríguez Jiménez C.   +8 more
europepmc   +1 more source